Tyr Pharma stock rated Hold after mixed trial results for efzofitimod; promising secondary data, but there remains uncertainty. Find out why ATYR is a Hold.

Marqeta is evolving with record EBITDA, strong TPV growth, and global expansion, though cash flow execution remains key. See ...

Loyalty is no longer something you buy. It is something you build. As more Gen-Zers come of age and Gen-Alpha starts to ...

STBL, a governance token by Tether co-founder, begins trading on Binance Alpha, giving early investors control over protocol ...

Manisha Mehta, 14, recently presented a paper at a global tech summit. An app aimed at parents is in the works. AI must be ...

Shruti, a college student, turns to ChatGPT for help and advice, sparking questions about AI's role in society.

Cellectar Biosciences, Inc. (Nasdaq: CLRB, "Cellectar”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, and ITM Isotope ...

Clayton Creswell Stansbury Jr., a Morgan State University psychology professor, died Aug. 30 at Future Care Lochearn. He was ...

Gwynedd Mercy University recently welcomed its newest cohort of the Griffin Scholars Program (GSP) at a reception in ...